Cooper Companies (NASDAQ:COO) Research Coverage Started at The Goldman Sachs Group

The Goldman Sachs Group started coverage on shares of Cooper Companies (NASDAQ:COO) in a report issued on Wednesday morning, Marketbeat reports. The firm issued a sell rating and a $64.00 target price on the medical device company’s stock.

Several other brokerages also recently issued reports on COO. Mizuho cut their price target on Cooper Companies from $105.00 to $90.00 and set an “outperform” rating for the company in a report on Wednesday, July 16th. BNP Paribas upgraded shares of Cooper Companies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 22nd. Robert W. Baird reduced their target price on shares of Cooper Companies from $97.00 to $85.00 and set an “outperform” rating for the company in a report on Thursday, August 28th. Loop Capital set a $100.00 price target on shares of Cooper Companies in a report on Tuesday, June 17th. Finally, Piper Sandler cut their price objective on shares of Cooper Companies from $105.00 to $83.00 and set an “overweight” rating for the company in a research report on Thursday, August 28th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $84.75.

Cooper Companies Stock Up 1.9%

Shares of COO stock opened at $70.46 on Wednesday. Cooper Companies has a 52-week low of $61.78 and a 52-week high of $109.37. The stock has a market cap of $14.01 billion, a price-to-earnings ratio of 34.71, a PEG ratio of 1.81 and a beta of 1.02. The firm’s 50-day moving average is $69.69 and its 200-day moving average is $74.16. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 2.12.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $1.07 by $0.03. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the previous year, the business earned $0.96 earnings per share. The business’s revenue was up 5.7% compared to the same quarter last year. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. Sell-side analysts predict that Cooper Companies will post 3.98 EPS for the current year.

Cooper Companies declared that its Board of Directors has approved a stock buyback program on Wednesday, September 17th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical device company to purchase up to 15.4% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In related news, CEO Albert G. White III acquired 10,000 shares of the company’s stock in a transaction on Friday, September 5th. The stock was purchased at an average cost of $68.39 per share, with a total value of $683,900.00. Following the acquisition, the chief executive officer directly owned 226,151 shares of the company’s stock, valued at approximately $15,466,466.89. The trade was a 4.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Daniel G. Mcbride bought 3,000 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The shares were bought at an average price of $65.04 per share, with a total value of $195,120.00. Following the completion of the transaction, the chief operating officer owned 63,120 shares in the company, valued at approximately $4,105,324.80. This trade represents a 4.99% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 17,975 shares of company stock valued at $1,216,346 in the last quarter. Corporate insiders own 1.98% of the company’s stock.

Institutional Investors Weigh In On Cooper Companies

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Cooper Companies by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 24,254,677 shares of the medical device company’s stock valued at $1,725,963,000 after buying an additional 421,423 shares during the period. State Street Corp boosted its position in shares of Cooper Companies by 1.2% during the 2nd quarter. State Street Corp now owns 8,659,741 shares of the medical device company’s stock worth $616,227,000 after acquiring an additional 104,910 shares in the last quarter. Geode Capital Management LLC increased its stake in Cooper Companies by 2.5% in the second quarter. Geode Capital Management LLC now owns 5,205,615 shares of the medical device company’s stock valued at $368,893,000 after acquiring an additional 127,907 shares during the last quarter. JPMorgan Chase & Co. raised its position in Cooper Companies by 3.4% during the first quarter. JPMorgan Chase & Co. now owns 5,177,008 shares of the medical device company’s stock valued at $436,681,000 after purchasing an additional 172,485 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in Cooper Companies by 17.0% during the first quarter. Goldman Sachs Group Inc. now owns 4,734,327 shares of the medical device company’s stock worth $399,340,000 after purchasing an additional 686,751 shares during the last quarter. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.